NASDAQ:NTRA

Natera Stock Forecast, Price & News

$102.88
-0.38 (-0.37 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$101.93
$105.60
50-Day Range
$86.05
$115.92
52-Week Range
$43.20
$127.19
Volume2.50 million shs
Average Volume902,020 shs
Market Capitalization$9.05 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.32
30 days | 90 days | 365 days | Advanced Chart
Receive NTRA News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.


Natera logo

About Natera

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.71 out of 5 stars

Medical Sector

283rd out of 2,097 stocks

Medical Laboratories Industry

6th out of 40 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Natera (NASDAQ:NTRA) Frequently Asked Questions

Is Natera a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Natera stock.
View analyst ratings for Natera
or view top-rated stocks.

What stocks does MarketBeat like better than Natera?

Wall Street analysts have given Natera a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Natera wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Natera's next earnings date?

Natera is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Natera
.

How were Natera's earnings last quarter?

Natera, Inc. (NASDAQ:NTRA) released its quarterly earnings data on Thursday, May, 6th. The medical research company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.31. The medical research company earned $152.32 million during the quarter, compared to analyst estimates of $114.42 million. Natera had a negative trailing twelve-month return on equity of 59.71% and a negative net margin of 57.47%. Natera's quarterly revenue was up 62.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.45) earnings per share.
View Natera's earnings history
.

How has Natera's stock price been impacted by COVID-19 (Coronavirus)?

Natera's stock was trading at $31.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NTRA stock has increased by 231.7% and is now trading at $102.88.
View which stocks have been most impacted by COVID-19
.

What guidance has Natera issued on next quarter's earnings?

Natera updated its FY 2021 earnings guidance on Thursday, May, 27th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $550 million-$575 million, compared to the consensus revenue estimate of $514.68 million.

What price target have analysts set for NTRA?

12 brokers have issued 12-month price objectives for Natera's shares. Their forecasts range from $60.00 to $150.00. On average, they anticipate Natera's stock price to reach $122.73 in the next year. This suggests a possible upside of 19.3% from the stock's current price.
View analysts' price targets for Natera
or view top-rated stocks among Wall Street analysts.

Who are Natera's key executives?

Natera's management team includes the following people:
  • Dr. Matthew Rabinowitz, Co-Founder & Exec. Chairman (Age 48, Pay $514.26k)
  • Mr. Steve Chapman, CEO, Pres & Director (Age 42, Pay $792.17k)
  • Mr. Jonathan Sheena, Co-Founder & Director (Age 48, Pay $293.91k)
  • Mr. Michael Brophy, Chief Financial Officer (Age 41, Pay $631.73k)
  • Mr. Robert A. Schueren, Chief Operating Officer (Age 59, Pay $691.17k)
  • Mr. Eric A. Evans, Chief Scientific Officer
  • Mr. Daniel Rabinowitz L.L.M., LL.M., Sec. & Gen. Counsel
  • Mr. Phil Grinnell, VP of Sales
  • Dr. Ramesh Hariharan, VP of Marketing & Medical Education
  • Paul Greenland, VP of Corp. Marketing

What is Steve Chapman's approval rating as Natera's CEO?

158 employees have rated Natera CEO Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among Natera's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Natera's key competitors?

What other stocks do shareholders of Natera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).

When did Natera IPO?

(NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

What is Natera's stock symbol?

Natera trades on the NASDAQ under the ticker symbol "NTRA."

Who are Natera's major shareholders?

Natera's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.34%), Fred Alger Management LLC (6.57%), JPMorgan Chase & Co. (3.75%), Orbimed Advisors LLC (2.50%), Ameriprise Financial Inc. (2.30%) and Gilder Gagnon Howe & Co. LLC (1.69%). Company insiders that own Natera stock include Daniel Rabinowitz, Gail Boxer Marcus, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Roy D Baynes, Steven Leonard Chapman and Todd C Cozzens.
View institutional ownership trends for Natera
.

Which institutional investors are selling Natera stock?

NTRA stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Granite Investment Partners LLC, Fred Alger Management LLC, Bridger Management LLC, Canada Pension Plan Investment Board, BNP Paribas Arbitrage SA, Prudential Financial Inc., and Kornitzer Capital Management Inc. KS. Company insiders that have sold Natera company stock in the last year include Daniel Rabinowitz, Gail Boxer Marcus, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Roy D Baynes, Steven Leonard Chapman, and Todd C Cozzens.
View insider buying and selling activity for Natera
or view top insider-selling stocks.

Which institutional investors are buying Natera stock?

NTRA stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Lord Abbett & CO. LLC, Holocene Advisors LP, D. E. Shaw & Co. Inc., JPMorgan Chase & Co., Voloridge Investment Management LLC, Principal Financial Group Inc., and Principal Financial Group Inc..
View insider buying and selling activity for Natera
or or view top insider-buying stocks.

How do I buy shares of Natera?

Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Natera's stock price today?

One share of NTRA stock can currently be purchased for approximately $102.88.

How much money does Natera make?

Natera has a market capitalization of $9.05 billion and generates $391.01 million in revenue each year. The medical research company earns $-229,740,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis.

How many employees does Natera have?

Natera employs 1,815 workers across the globe.

What is Natera's official website?

The official website for Natera is www.natera.com.

Where are Natera's headquarters?

Natera is headquartered at 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070.

How can I contact Natera?

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090 or via email at [email protected]


This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.